NADMED raised a lot of interest among the VC investors at Nordic Life Science days 2022 in Malmö, Sweden. Investors were particularly enthusiastic about NADMED’s first three quarters’ business development. NADMED is currently growing rapidly selling...
Leaders in the aging and longevity field are gathered in the 9th Aging Research and Drug Discovery meeting in Copenhagen from 29th of August. NADMED is joining the event where the experts will describe the latest progress in the molecular, cellular and organismal...
NADMED’s new website was published in the end of June 2022. Designers’ goal was to build a visually rewarding yet simple site which will provide the necessary information about NADMED’s technology, products and services for researchers, medical...
The Q-NADMED Kit for blood received CE marking at the end of May. NADMED’s kit is the only NAD measuring kit to have received marking which indicates that the kit complies with EU In Vitro Diagnostic Directive (IVDD 98/79/EC) so it can be brought to market for...
NADMED’s board is full of excellence. The new board members are Juha Tuominen, former CEO of HUS, and Ilkka Salonen, former CFO of YIT Oyj and Neste Oyj. Welcome! Prof. Anu Wartiovaara continues as the CoB and Sebastian Soidinsalo as a board...
